Cite
HARVARD Citation
Sano, T. et al. (2018). Recombinant human soluble thrombomodulin as an anticoagulation therapy improves recurrent miscarriage and fetal growth restriction due to placental insufficiency – The leading cause of preeclampsia. Placenta. pp. 1-6. [Online].